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Abstract
Background: To evaluate the efficacy and safety of half-dose photodynamic therapy (PDT combined with ranibizumab
for polypoidal choroidal vasculopathy (PCV). PCV is commonly treated with a combination of anti-vascular endothelial
growth factor and standard-dose photodynamic therapy (PDT). Choroidal ischemia and visual loss can be resulted from
the standard-dose PDT. Half-dose PDT has proved to produce similar results and safety profile in treating central serous
chorioretinopathy. Half-dose PDT may offer an alternative for PCV cases where the damage to choroidal vasculature
maybe less. Here, we report the efficacy of treating PCV cases with combination of ranibizumab and half-dose PDT.
Methods: In this prospective, non-comparative, interventional case series, 19 treatment-naive eyes were treated
with combined half-dose PDT and ranibizumab. All subjects were followed up for 12 months with measurement
of best-corrected visual acuity (BCVA), central foveal thickness (CFT) by optical coherence tomography. Indocyanine green
angiogram (ICG) was performed every 3-monthly, and subjects assessed in terms of polyp regression rates,
changes in vision and central foveal thickness, need to repeat half-dose PDT. Subgroup analysis was performed
based on ICG features.
Results: The mean logMAR BCVA improved from 0.64 at baseline to 0.41 at 12 months. The mean CFT improved from
459.6mum at baseline to 384.2mum at 12 months. The difference between baseline BCVA and CFT and that at 12
months were statistically significant (both P = 0.03). Polyp regression rate after one half-dose PDT was 42.1 %. This was
61.5 % in the polyp-only group, while that in the branching-vascular-network (BVN) group was 0 % (P = <0.01).
Conclusion: Half-dose PDT combined with intravitreal ranibizumab was able to induce high polyp regression
rate in PCV cases that had one single polyp.
Keywords: Age related macular degeneration, Half-dose, Half-fluence, Photodynamic therapy, Polypoidal
choroidal vasculopathy, Ranibizumab, Verteporfin
Background
Polypoidal choroidal vasculopathy (PCV) is character-
ized by polypoidal lesions originating beneath the retinal
pigment epithelium (RPE) [1, 2]. It is still being debated
whether it is a subtype of wet age-related macular de-
generation or an independent pathology [3, 4]. Its re-
ported prevalence is higher in Asian population than
Caucasians, and the rate varies between 22.3 % and
54.7 % among Asian countries [5].
Clinically, these polyps appear as protruding elevated
orange red lesions. These exist either as isolated polyps,
or are associated with a branching vascular network
(BVN) [1, 5]. The course of polyps in PCV is variable,
and can be associated with serous exudation and
hemorrhage which may lead to RPE detachments. At
times, it also gives rise to subretinal fluid (SRF) with
detachments of neurosensory retina [5, 6].
The recommended treatment for PCV is either com-
bination of standard-fluence verteporfin PDT and intra-
vitreal injections of anti-vascular endothelial growth
factors (anti-VEGFs) at monthly intervals, or a standard-
fluence verteporfin PDT [1, 7]. The mechanism of action
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of PDT is postulated to be short-term choriocapillaris
hypoperfusion and long-term choroidal vascular remod-
eling, leading to reduction in choroidal congestion, vas-
cular hyperpermeability, and extravascular leakage [8].
Despite the demonstrated efficacy of PDT with full-
dose verteporfin in inducing polyp regression, potential
adverse events exists, such as secondary RPE changes at
the site of PDT laser application, which is the result of
hypoxic damage caused by choriocapillaris occlusion [9].
Some have demonstrated transient reduction in macular
function and even reduction in choroidal circulation fol-
lowing PDT [10]. Choroidal neovascularization (CNV)
can develop after PDT for other retinal conditions such
as central serous chorioretinopathy (CSC) due to chor-
oidal ischaemia.
To reduce the risks of PDT, the intensity of treatment
can be reduced, either by reducing the fluence of PDT
or by reducing the dose of verteporfin. Recently, there
have been reports of success with half-fluence PDT in
the treatment of PCV combined with anti-VEGF injec-
tions [12–14]. In the case of CSC, half-dose PDT was
tried and good results were shown [11]. Half-dose PDT
was also found to be more effective than half-fluence
PDT in the treatment of CSC [15]. However, we are not
aware of any studies looking into the efficacy of half-
dose PDT in the treatment of PCV. The purpose of this
study was to determine the efficacy of half-dose PDT for
the treatment of PCV, in combination with intravitreal
ranibizumab.
Methods
This was a prospective, consecutive, open-label, non-
comparative interventional study, carried out at two
sites: the University of Hong Kong, and the Peking Uni-
versity People’s Hospital. This study adhered to the Dec-
laration of Helsinki and ethics approval was obtained
from the Institutional Review Boards of the two sites
(Institutional Review Board of the University of Hong
Kong/Hospital Authority Hong Kong West Cluster ref-
erence number UW12-207). Same protocol was adopted
at the two sites, and the study was performed simultan-
eously. Informed consent was obtained from all subjects.
The main inclusion criteria were 1) treatment naïve
PCV as characterized by the presence of polyps or
branching vascular networks (BVN) on indocyanine
green angiogram (ICG), 2) age over 50 years, 3)
best-corrected visual acuity (BCVA) of 0.30 or worse
(LogMAR, hereafter), and 4) a greatest linear dimension
(GLD) of 5400 μm or less. Exclusion criteria were 1)
prior treatment with either intravitreal injections of anti-
VEGF of any kind or verteporfin PDT, 2) the presence of
vitreous hemorrhage, 3) extensive subretinal hemorrhage
preventing proper imaging/PDT from being performed,
4) an area of scar tissue accounting for 50 % or more of
the lesion, and 5) presence of other retinal diseases such
as diabetic retinopathy.
All consecutive eligible subjects were recruited from 1
Sep 2012 to 30 Jun 2013, and underwent comprehensive
baseline ophthalmic examination and at monthly inter-
vals for 12 months. These included BCVA (logMAR,
hereafter), macular examination with a 90-D lens, fun-
dus photography, and optical coherence tomography
(OCT) (Heidelberg Spectralis; Heidelberg Engineering,
Heidelberg, Germany). Fluorescein angiogram (FA) and
indocyanine green angiogram (ICG) were performed
using a scanning laser ophthalmoscope (Heidelberg Ret-
inal Angiography; Heidelberg Engineering, Heidelberg,
Germany) at baseline and every 3 months.
All subjects received a combination of intravitreal
ranibizumab (Lucentis; Novartis AG, Basel, Switzerland)
and half-dose verteporfin (Visudyne; Novartis AG, Basel,
Switzerland) PDT after enrollment as initial treatment.
The half-dose PDT was given within 7 days after intra-
vitreal ranibizumab. Ranibizumab (0.5 mg/0.05 ml) was
injected 3.5 mm post-limbus using a 30-gauge needle
under aseptic condition. Half-dose PDT was performed
using half of the normal dose of verteporfin (3 mg/m2
verteporfin). Verteporfin was infused over 10 min,
followed by delivery of laser at 689 nm at 15 min from
the commencement of infusion. The laser spot size was
determined by adding 1000 μm to the entire PCV lesion,
including any polyps and/or BVN as seen on ICG. A
total light energy of 50 J/cm2 over 83 s was delivered.
Subjects were reassessed monthly. If there was disease
activity on OCT, defined as presence of any subretinal
and/or intraretinal fluid, ranibizumab would be given.
FA and ICG were repeated every 3 months, if 1) no
polyps or BVN were seen on ICG, and no disease activ-
ity on OCT and FA (defined as presence of FA leakage),
no retreatment would be given; 2) if polyps were seen
and there was FA / OCT disease activity, half-dose PDT
and ranibizumab would be repeated; 3) if only BVN was
seen without polyps, and there was FA/OCT disease ac-
tivity, only ranibizumab would be given; and 4) if only
BVN was seen without polyps, and there was no FA/
OCT disease activity, no re-treatment would be given.
Primary outcomes measured were the change in
BCVA and the rate of polyp/BVN regression after half-
dose PDT during the study period. Secondary outcomes
included change in central foveal thickness (CFT) on
OCT and the number of half-dose PDT sessions required
to induce polyp/BVN regression. Subgroup analysis was
performed between cases that had polyp-only and cases
with BVN on ICG.
Microsoft Excel (Microsoft Excel 2011) was used for
data collection; SPSS was used for statistical analysis
(SPSS Version 19). Chi-square test was used to evaluate
the differences between the proportions of subjects
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achieving the measurement endpoints. Fisher’s exact test
was used when the expected frequency of a cell in a
table was less than 5. Two sample t-tests were used to
measure differences in the continuous variables, such as
age and CFT, between the treatment groups. A probabil-
ity level of <0.05 was used to measure statistical signifi-
cance. All of the tests were two-sided.
Results
Demographics and summary of the responses are shown
in the Table 1. Nineteen eyes of 19 subjects were re-
cruited (13 at the University of Hong Kong, 6 at the
Peking University People’s Hospital). Ten of them were
male (52.6 %), and the mean age was 64.8 ± 15.2 years
(range 22 to 88 years). Thirteen eyes (67.4 %) had polyps
only, 7 of which had only 1 polyp, while 6 had more
than 1 polyp (range 2 to 5). Six eyes (32.6 %) had both
polyps and BVN, and amongst the cases with BVN, all
had more than 1 polyp.
The overall mean BCVA were 0.64 ± 0.37 at baseline,
0.43 ± 0.22 at 3 months, 0.43 ± 0.26 at 6 months, and
0.41 ± 0.25 at 12 months. The mean CFT were 459.6 ±
167.3 μm at baseline, 339.0 ± 175.8 μm at 3 months,
355.0 ± 181.1 μm at 6 months, and 384.2 ± 194.9 μm at
12 months (Figs. 1 and 2). The difference between
baseline BCVA and CFT and that at 12 months were sta-
tistically significant (P = 0.03, P = <0.01 respectively).
Visual acuity in the polyp-only group was better than
the BVN group in all time points, but the difference did
not differ statistically (P = 0.19 at baseline, P = 0.90 at 3
months, P = 0.28 at 6 months, P = 0.98 at 12 months).
The mean number of ranibizumab injections was 2.37 ±
1.5 (range 1 to 7) throughout the 12-month period.
With 1 session of half-dose PDT combined with 1 in-
jection of intravitreal ranibizumab, complete polyp re-
gression (Figs. 3 and 4) was achieved in 8 out of 19 eyes
(42.1 %). Out of these 8 cases, 7 of which (87.5 %) had
only 1 polyp at baseline, and the remaining one case had
2 polyps.
For the remaining 11 eyes (57.9 %), after one session
of half-dose PDT, in 8 eyes, although polyps persisted on
ICG, the polyps size reduced. In the remaining 3 eyes,
the polyps did not change after one session of half-dose
PDT. All the BVN did not change after one session of
half-dose PDT.
Polyp regression rate after one single half-dose PDT
session was 61.5 % in the polyp-only group, while that in
the BVN group was 0 % (P = <0.01). Of particular inter-
est, the polyp regression rate was 100 % for those that
had only 1 polyp and no BVN at baseline (7 out of 7
eyes).
Re-treatment rate of half-dose PDT in the polyp-only
group (n = 13) was 38.5 %, and the mean number of
half-dose PDT sessions was 1.38 (range 1 to 2). That in
Table 1 Background characteristics and treatment outcomes of the subjects
Subject Age/
Sex
Baseline ICG
features
Number
of Half-dose
PDT
BCVA (logMAR) Number of
ranibizumab
injections
ICG findings at 12-month Complications
Baseline 3-month 6-month 12-month Polyp BVN
1 60/F 1 polyp 1 0.7 0.4 0.3 0.3 3 Regressed / Nil
2 60/F 1 polyp 1 1.0 0.55 0.3 0.3 3 Regressed / Nil
3 77/M 1 polyp 1 0.3 0.3 0.2 0.2 2 Regressed / Nil
4 68/F 1 polyp 1 0.3 0.3 0.4 0.3 4 Regressed / Nil
5 66/M 1 polyp 1 0.0 0.1 0.0 0.1 1 Regressed / Nil
6 71/M 1 polyp 1 0.1 0.1 0.1 0.1 1 Regressed / Nil
7 55/M 1 polyp 1 1.3 0.4 0.4 0.4 2 Regressed / Nil
8 63/M 2 polyps 1 0.7 0.4 0.4 0.3 1 Regressed / Nil
9 52/F 2 polyps 2 1.0 0.7 0.7 0.6 2 Regressed / Nil
10 88/M 2 polyps 2 0.55 0.4 0.4 0.4 2 Regressed / Nil
11 78/M 2 polyps 2 0.7 0.4 0.3 0.4 2 Regressed / Nil
12 75/F 2 polyps 2 0.55 0.3 0.4 0.3 1 Regressed / Nil
13 60/F 5 polyps 2 1.0 0.7 1.0 1.0 7 Regressed / Nil
14 69/M BVN + 2 polyps 2 0.4 0.4 0.55 0.4 2 Regressed Persisted Nil
15 72/F BVN + 2 polyps 2 0.7 0.7 0.55 0.55 2 Regressed Persisted Nil
16 55/F BVN + 2 polyps 3 1.3 1.0 1.0 1.0 5 Regressed Persisted Nil
17 84/F BVN + 2 polyps 2 0.3 0.3 0.4 0.3 1 Regressed Persisted Nil
18 76/M BVN + 3 polyps 2 0.55 0.4 0.3 0.3 2 Regressed Persisted Nil
19 81/M BVN + 5 polyps 2 0.7 0.4 0.55 0.55 2 Regressed Persisted Nil
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the BVN group was 100 % and the mean number of ses-
sions was 2.17 (range 2 to 3) (P = 0.04).
The 8 cases that had polyp regressed after one session
of half-dose PDT required no further treatments with
half-dose PDT. Of the 6 eyes with BVN, none showed
regression throughout the 12-month period. However,
after a mean of 2.17 (range 2 to 3) sessions of half-dose
PDT, no disease activity was seen despite persistence of
the BVN on ICG.
Retreatment with ranibizumab was required in both
groups. Overall mean number of ranibizumab in the 12-
month period was 2.37 ± 1.5 (range 1 to 7). That in the
polyp-only group was 2.38; while that in the BVN group
was 2.33, and the difference was not statistically signifi-
cant (P = 0.70).
No significant adverse events occurred during the 12-
month period. No loss of visual acuity of more than 3
lines in any of the eyes. No systemic side effects were
observed.
Discussion
PDT is an established treatment modality for PCV [1,
27]. The mechanism of action involves a vaso-occlusive
effect. When PDT activates the photosensitizer vertepor-
fin at the laser-applied area, it induces vascular throm-
bosis, reduced perfusion and PCV regression [8, 9]. A
high polyp regression rate of 82 to 95 % with PDT
monotherapy was reported [8, 16, 17]. The standard
PDT dosage had been shown in studies to cause chor-
oidal ischaemia, RPE atrophy, secondary CNV [18] and
fibrous scarring [18] that limit the visual gain despite
PCV regression. In addition, persistence of BVN with
PCV recurrence is not uncommon after treatment [9].
Repeated PDTs would produce additive adverse effects
[19]. As a result, the long-term efficacy of PDT is often
disappointing. In a prospective study of 65 eyes, the
mean BCVA decreased an average of 0.21 logMAR units
at 5 years after initial PDT. In another retrospective
study of 43 eyes [20], BCVA decreased to below baseline
in all eyes after 3 years. The authors attributed the un-
favorable long-term outcomes to foveal atrophy [20],
PCV recurrence [20, 21] and CNV development [20].
Therefore, methods to reduce the adverse effects of PDT
are necessary. One approach is to minimize the treat-
ment intensity by reducing the fluence; the other is to
reduce the dose of verteporfin.
Initial studies showed favorable outcomes with reduced-
fluence PDT in treating PCV [12, 14, 22, 23]. Yamashita et
al. demonstrated that, in a prospective study of 38 eyes
treated with reduced-fluence PDT, the mean BCVA im-
proved from 0.43 to 0.29 logMAR units at 2 years [22]. The
mean treatment sessions were 1.9 only. The BCVA
remained stable or improved in 95 %. Polyp regressed in 92
% at 3 months. When reduced-fluence PDT was used in
combination with intravitreal ranibizumab, Ricci et al.
showed a significant improvement of BCVA from 0.45 to
0.29 logMAR units at 1 year [23]. The BCVA remained
stable or improved in 95 %. Polyp regressed in 94 %.
Sakurai et al. showed a significant improvement of BCVA
from 0.55 to 0.38 logMAR units at 1 year, and fewer ranibi-
zumab treatments were required [12]. Sagong et al. showed
in a prospective study that combining intravitreal bevacizu-
mab and reduced-fluence PDT, the BCVA improved from
0.76 to 0.46 logMAR at 1 year [14].
Concerning the problems with reduced-fluence PDT, a
high rate of BVN persistence of 84 % at 3 months [22]
and 65 % at 1 year were reported [23]. Subretinal
hemorrhage within 3 months after PDT (13 %, Yamashita
et al. [22]), persistent mild choriocapillary non-perfusion
(18.8 %, Sagong et al. [14]) and persistent mild-to-moderate
choriocapillary non-perfusion (20 %, Yoshida et al. [13])
Fig. 1 The changes in mean logMAR best-corrected visual acuity
over time
Fig. 2 The changes in mean central foveal thickness on optical
coherence tomography over time
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had also been reported. Therefore, despite good initial vis-
ual outcome, the risk of polyp recurrence and choroidal is-
chaemia still exist even when the fluence had been reduced.
Half-dose PDT has been widely used for the treatment
of CSC [11, 24] and is considered to have fewer side effects
than standard-dose PDT [24]. Improvement in visual acuity
[11, 24], contrast sensitivity, microperimetric retinal sensi-
tivity and retinal function on multifocal electroretinography
[25] had been demonstrated following treatment of CSC
with half-dose PDT. Nicolo et al. evaluated the efficacy and
safety of half-dose versus half-fluence PDTand showed that
half-dose PDT induced more rapid reabsorption of fluid
and more lasting effect with equal safety [15]. Since both
CSC and PCV have similar underlying pathophysiology of
choroidal hyperpermeability [26, 27], half-dose PDT might
also be more effective than half-fluence PDT in PCV treat-
ment. To the best of our knowledge, this is the first study
to investigate the efficacy of half-dose PDT and ranibizu-
mab in PCV.
This study showed that half-dose PDT combined with
ranibizumab was highly successful in treating single
small polyp PCVs, but it appeared to be less effective if
there were BVN and/or multiple polyps were present. In
patients who had a single small polyp, we observed
polyp regression or disease activity resolution for at least
9 months after treatment. For cases with more than 1
polyp, although a single session of half-dose PDT was
not able to induce polyp regression in majority of the
cases, repeated treatment achieved polyp regression at a
later time point. Although the current regimen was not
able to cause BVN regression, it appeared that it was
able to suppress the disease activity associated with the
BVN. Our result suggested that the number of polyps
and the presence of BVN were important prognostic
Fig. 3 This was the indocyanine green angiogram of subject 6. Baseline logMAR visual acuity was 0.1, and remained at 0.1 throughout. There was
only 1 single polyp, which regressed after only one session of half-dose photodynamic therapy and one injection of ranibizumab. a Showed the
appearance of the polyp at baseline on ICG; and b the appearance at 3 months
Fig. 4 This was the optical coherence tomography of subject 6 at (a) baseline, and (b) at 3 months. This showed the complete resolution of
subretinal fluid
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factors that determined the success rate of combined
half-dose PDT and ranibizumab.
Another point to note is that subjects with polyp-only
or had BVN did not behave differently in terms of the
visual acuity improvement and number of ranibizumab
injections required. This was probably because of the ef-
ficacy of the half-dose PDT. For the polyp-only cases it
was rather straightforward in that regression of the le-
sions led to clinical improvement; in subjects with BVN,
one explanation is that even though the half-dose PDT
did not lead to regression of the BVN, it induced stabil-
ity of the lesion. That was probably why clinically these
cases behaved well despite the persistence of the lesion
on ICG. Whether the endpoint of PDT (be it half-dose,
half-fluence, or standard) is complete regression of the
lesions or not requires further investigation.
The limitations of this study included small sample
size, the lack of comparison with standard-dose PDT,
the lack of comparion with half-fluence PDT, and the
heterogeneity in lesion types recruited. However, the
heterogeneity of subjects may be a reflection of the high
variability of the disease itself. Our findings suggested
that half-dose PDT is highly successful for selected cases
of PCV. Future controlled studies are warranted to de-
termine the long-term efficacy of half-dose PDT, to
identify the optimal lesion type for treatment, and to
compare the efficacy and safety with standard-dose PDT.
Conclusion
Half-dose PDT combined with intravitreal ranibizumab
was able to induce high polyp regression rate in PCV
cases that had one single polyp.
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